Pages that link to "Item:Q1886332"

The following pages link to Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999) (Q1886332):

Displayed 50 items.

• Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy (Q264091) ‎ (← links)
• Angiogenesis model with Erlang distributed delays (Q335233) ‎ (← links)
• Local controllability and optimal control for a model of combined anticancer therapy with control delays (Q335260) ‎ (← links)
• The nature of Hopf bifurcation for the Gompertz model with delays (Q409877) ‎ (← links)
• Multi-input optimal control problems for combined tumor anti-angiogenic and radiotherapy treatments (Q415424) ‎ (← links)
• On an extension of a mathematical model for tumor anti-angiogenesis (Q425828) ‎ (← links)
• Angiogenesis inhibition and tumor-immune interactions with chemotherapy by a control set-valued method (Q541886) ‎ (← links)
• A generalization of Gompertz law compatible with the Gyllenberg-Webb theory for tumour growth (Q543860) ‎ (← links)
• Analysis of the Hopf bifurcation for the family of angiogenesis models (Q549750) ‎ (← links)
• Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function (Q630983) ‎ (← links)
• Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis (Q657013) ‎ (← links)
• The response to antiangiogenic anticancer drugs that inhibit endothelial cell proliferation (Q856106) ‎ (← links)
• Stability and controllability issues in mathematical modeling of the intensive treatment of leukemia (Q887122) ‎ (← links)
• Analysis of the Hopf bifurcation for the family of angiogenesis models. II: The case of two nonzero unequal delays (Q902503) ‎ (← links)
• A theoretical study of the response of vascular tumours to different types of chemotherapy (Q955502) ‎ (← links)
• Metamodeling tumor-immune system interaction, tumor evasion and immunotherapy (Q955506) ‎ (← links)
• Resonance of the epidemic threshold in a periodic environment (Q999288) ‎ (← links)
• Global stability and optimisation of a general impulsive biological control model (Q1038254) ‎ (← links)
• On optimal delivery of combination therapy for tumors (Q1042733) ‎ (← links)
• Evaluating the efficacies of maximum tolerated dose and metronomic chemotherapies: a mathematical approach (Q1619565) ‎ (← links)
• Understanding the antiangiogenic effect of metronomic chemotherapy through a simple mathematical model (Q1620068) ‎ (← links)
• Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: a dynamic energy budget (DEB) approach (Q1642581) ‎ (← links)
• An optimal control approach for the treatment of solid tumors with angiogenesis inhibitors (Q1649031) ‎ (← links)
• Optimization of combined leukemia therapy by finite-dimensional optimal control modeling (Q1682981) ‎ (← links)
• Modeling of tumor growth incorporating the effects of necrosis and the effect of Bevacizumab (Q1694227) ‎ (← links)
• Closed-loop control of tumor growth by means of anti-angiogenic administration (Q1714906) ‎ (← links)
• Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice (Q1715176) ‎ (← links)
• Chemotherapy of vascularised tumours: role of vessel density and the effect of vascular ``pruning'' (Q1716206) ‎ (← links)
• The dynamical behaviors for a class of immunogenic tumor model with delay (Q1784122) ‎ (← links)
• Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers (Q1790751) ‎ (← links)
• Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis (Q1794472) ‎ (← links)
• A dynamic programming approach for approximate optimal control for cancer therapy (Q1949602) ‎ (← links)
• Analysis of a stochastic tumor-immune model with regime switching and impulsive perturbations (Q1988874) ‎ (← links)
• Mathematical modeling of tumor-immune competitive system, considering the role of time delay (Q2007671) ‎ (← links)
• On the role of the objective in the optimization of compartmental models for biomedical therapies (Q2025280) ‎ (← links)
• Combined therapy for treating solid tumors with chemotherapy and angiogenic inhibitors (Q2033852) ‎ (← links)
• Tumour growth and its treatment response delineate with mathematical models (Q2097096) ‎ (← links)
• Stability analysis of the family of tumour angiogenesis models with distributed time delays (Q2199481) ‎ (← links)
• What mathematical models can or cannot do in glioma description and understanding (Q2206309) ‎ (← links)
• Bifurcation of nontrivial periodic solutions for a Beddington-DeAngelis interference model with impulsive biological control (Q2337618) ‎ (← links)
• Effect of treatment on the global dynamics of delayed pathological angiogenesis models (Q2341145) ‎ (← links)
• A bi-parametric model for the tumour angiogenesis and antiangiogenesis therapy (Q2390073) ‎ (← links)
• A dynamical model of tumour immunotherapy (Q2453787) ‎ (← links)
• Mesoscopic and continuum modelling of angiogenesis (Q2512944) ‎ (← links)
• A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences (Q2565761) ‎ (← links)
• Tumour growth control: analysis of alternative approaches (Q2693199) ‎ (← links)
• Optimisation of Cancer Drug Treatments Using Cell Population Dynamics (Q2820387) ‎ (← links)
• Tumor Development Under Combination Treatments with Anti-angiogenic Therapies (Q2820388) ‎ (← links)
• Periodic and chaotic oscillations in a tumor and immune system interaction model with three delays (Q2821527) ‎ (← links)
• Qualitative analysis of tumor growth model under antiangiogenic therapy - choosing the effective operating point and design parameters for controller design (Q2830286) ‎ (← links)